Symbiotec Pharmalab Ltd. IPO
IPO Timeline
Category-wise Subscription
| Category | Sub (x) | Offered | Bid For | Amt (Cr)* |
|---|---|---|---|---|
| QIB | 72.96x | 8,876,516 | 647,629,440 | ₹877 Cr |
| NII (HNI) | 77.22x | 2,662,956 | 205,638,555 | ₹263 Cr |
| Retail | 13.42x | 6,213,563 | 83,371,905 | ₹614 Cr |
| Σ Total | 1.53x | 33,407 | 50,970 | ₹3 Cr |
Only available investor categories are shown. Amount is auto-calculated when shares offered and issue price are available.
Issue Details
Minimum Investment (Lot-wise)
| Category | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 15 | ₹14,820 |
| Retail (Max) | 13 | 195 | ₹192,660 |
| S-HNI (Min) | 14 | 210 | ₹207,480 |
| B-HNI (Min) | 67 | 1,005 | ₹992,940 |
Financial Statements Amount in ₹ Crore
| Metric | 31 Mar 2026 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Revenue | 872 | 756 | 723 |
| EBITDA | 232 | 206 | 177 |
| Profit After Tax | 110 | 97 | 100 |
| Net Worth | 1,159 | 821 | 721 |
| Total Assets | 1,781 | 1,580 | 1,295 |
| Reserves & Surplus | 1,146 | 810 | 710 |
| Total Borrowing | 388 | 541 | 247 |
Valuation & Key Ratios
Grey Market Premium (GMP)
GMP is an unofficial grey market indicator and does not guarantee actual listing price. Invest at your own risk.
Objects of the Issue
- Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the Company – 112.50
- General corporate purposes –
Company Overview
Incorporated in 2002, Symbiotec Pharmalab Ltd. is a pharmaceutical and biotechnology company engaged in the development and manufacturing of active pharmaceutical ingredients (APIs), nutritional ingredients, and specialty products. The company serves domestic and international markets across regulated and emerging regions.
With over 30 years of industry experience, Symbiotec Pharmalab has evolved from a lab-scale steroidal hormone API manufacturer in 1995 into an industrial-scale, backward-integrated manufacturing platform. The company has approvals from the United States Food and Drug Administration (US FDA), European Union Good Manufacturing Practices (EU-GMP), Ministry of Food and Drug Safety, Korea, and other global regulatory organisations.
As of June 30, 2025, the company operated two industrial-scale API manufacturing facilities with a maximum chemical synthesis capacity of 584.67 metric tonnes (MT) and fermentation capacity of 300 kilolitres.
Symbiotec Pharmalab focuses on research-driven manufacturing, quality compliance, and sustainable production processes. It supports the pharmaceutical, nutraceutical, and wellness industries by providing high-quality ingredients aligned with global standards.
Competitive Strengths:
- Global leadership in corticosteroid and steroidal hormone APIs.
- Long-standing relationships with domestic and international customers.
- Fully invested, multi-scale, vertically integrated manufacturing platform with sustainable practices and a strong regulatory track record.
- Continuous investment in research and development, supported by strong technological capabilities among Indian industry peers.
- Ability to leverage its scientific expertise and existing capabilities to expand its total addressable market and develop intellectual property-driven offerings.